PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of annaldermaAnnals of DermatologyThis ArticleInformation for AuthorsOnline Submission
 
Ann Dermatol. Aug 2012; 24(3): 370–372.
Published online Jul 25, 2012. doi:  10.5021/ad.2012.24.3.370
PMCID: PMC3412254
Efficacy of Finasteride 1.25 mg on Female Pattern Hair Loss; Pilot Study
Won-Jeong Kim, M.D.,1 Margaret Song, M.D.,1 Hyun-Chang Ko, M.D.,1 Byung-Soo Kim, M.D., Ph.D.,1,2 and Moon-Bum Kim, M.D., Ph.D.corresponding author1,2
1Department of Dermatology, Pusan National University School of Medicine, Pusan National University Hospital, Busan, Korea.
2Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
corresponding authorCorresponding author.
Corresponding author: Moon-Bum Kim, M.D., Ph.D., Department of Dermatology, Pusan National University Hospital, Pusan National University School of Medicine, 179 Gudeok-ro, Seo-gu, Busan 602-739, Korea. Tel: 82-51-240-7338, Fax: 82-51-245-9467, drkmp/at/hanmail.net
Received May 2, 2011; Revised September 20, 2011; Accepted September 20, 2011.
Dear Editor:
Although finasteride was approved only for male pattern baldness1, it has been in off-label use on female pattern hair loss (FPHL). A pilot study done on postmenopausal women showed that 1mg of finasteride had no effect on FPHL2. Following that report, 2.5 mg or 5 mg of finasteride in FPHL was shown to be effective in several case reports and a few studies3,4. This suggests that finasteride may be effective in FPHL, but its optimal dosage on FPHL needs to be clarified. Researchers have not described any dose-dependent side effect (1 mg; 11.9% vs. 5 mg; 4.6%)2-4, in women, administering the medication beyond what is efficacious is unreasonable. To determine whether 1.25 mg finasteride can be the minimal effective dosage on FPHL, we conducted a 28 week, open-labeled, prospective study for 18 normoandrogenic FPHL patients with finasteride 1.25 mg daily. All the patients had normal androgen, iron, ferritin level and normal thyroid function test at initial screening. The treatment efficacy was evaluated with the changes of hair density and thickness4 assessed by phototrichogram (Aramo-SG, Aram HUVIS Co., Seoul, Korea) and patients' and physician's global assessment a using 7-point scale score5. All premenopausal women (n=9) were informed of the potential risk of the finasteride on a male fetus. Fourteen patients completed the study, and their demographics and results were noted in Table 1. Three patients withdrew after treatment of 2~4 months because of no remarkable clinical improvement and another patient has been lost to follow-up. Baseline mean hair density was 101.7±27.14/cm2 and hair thickness was 53.4±10.3 µm. After 28 weeks of treatment, phototrichogram assessment demonstrated 5.87% mean increment (from 101.7±27.14 to 107.8±18.34/cm2, p=0.29) of hair density and 11.8% mean increment (from 53.4±10.3 to 60.1±10.4 µm, p=0.06) of hair thickness without statistical significance (paired t-test, SPSS 13.0; SPSS Inc., Chicago, IL, USA) (Fig. 1). Ten (71.4%) of the 14 patients rated their states as 'no change' and the physicians also recorded 'no change' in 9 (64.3%) patients, at the end of the study.
Table 1
Table 1
Baseline characteristics, folliscope assessment of hair density/thickness, and global assessment of enrolled patients before and 28 weeks after finasteride 1.25 mg/day treatment
Fig. 1
Fig. 1
The patients with improved physician's global assessment score (+1) after 7 months of daily finasteride 1.25 mg medication.
Though the clinical pattern of hair loss is different from men and women and the role of androgen in the pathogenesis of FPHL is unclear until now, it is believed that the pathogenesis of FPHL is similar with an inherited tendency of hair follicles to miniaturize progressively when exposed to dihydrotestosterone6,7. Price et al.2 reported that finasteride at 1 mg/day in a patient with FPHL failed to show slowing hair thinning, increasing growth, or improved appearance. Iorizzo et al.3 showed some improvement in 62% of patients with finasteride 2.5 mg daily and Yeon et al.4 also reported daily finasteride 5 mg was effective in FPHL, but Carmina and Lobo.8 reported the opposite result with the same dosage (5 mg/day). A previous report of finasteride 1.25 mg daily was limited to just four hyperandrogenic FPHL people9. This is the first study of daily finasteride 1.25 mg in normoandrogenic FPHL patients. In addition, most previous studies evaluate the efficacy through photographic assessment by patients and investigators8,9, but we used phototrichogram for objective evaluation of efficacy. In this study, patients with FPHL did not show a significant increase in hair growth, but hair density and thickness was minimally increased or constant without further hair loss even though the sample size was small and the duration of treatment was short. Most women with FPHL tend to experience more negative body-image, more social anxiety, and poor self-esteem than control subjects10. Therefore, we thought that subjects reporting 'no change' or 'slight increased' about their condition is meaningful in the treatment of FPHL. Previous studies reported drug-related adverse effect such as headache, depression, nausea, hot flushing, menstrual irregularity, or increased body hair in some patients2,4,6. However, no one reported drug-related symptoms during this study.
From this study, we found out that daily finasteride 1.25 mg medication for 28 weeks in FPHL patients show some measurable efficacy but it doesn't show objective clinical efficacy. Therefore, we suggest that a dose higher than 1.25 mg/day, more number of patients and longer duration of treatment are needed to confirm the effects of this clinical trial in normoandrogenic FPHL.
ACKNOWLEDGMENT
This study was supported by a grant of the Korean Heath Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (A070001).
1. Rogers NE, Avram MR. Medical treatments for male and female pattern hair loss. J Am Acad Dermatol. 2008;59:547–566. [PubMed]
2. Price VH, Roberts JL, Hordinsky M, Olsen EA, Savin R, Bergfeld W, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol. 2000;43:768–776. [PubMed]
3. Iorizzo M, Vincenzi C, Voudouris S, Piraccini BM, Tosti A. Finasteride treatment of female pattern hair loss. Arch Dermatol. 2006;142:298–302. [PubMed]
4. Yeon JH, Jung JY, Choi JW, Kim BJ, Youn SW, Park KC, et al. 5 mg/day finasteride treatment for normoandrogenic Asian women with female pattern hair loss. J Eur Acad Dermatol Venereol. 2011;25:211–214. [PubMed]
5. Roberts JL, Fiedler V, Imperato-McGinley J, Whiting D, Olsen E, Shupack J, et al. Clinical dose ranging studies with finasteride, a type 2 5alpha-reductase inhibitor, in men with male pattern hair loss. J Am Acad Dermatol. 1999;41:555–563. [PubMed]
6. Thai KE, Sinclair RD. Finasteride for female androgenetic alopecia. Br J Dermatol. 2002;147:812–813. [PubMed]
7. Trüeb RM. Swiss Trichology Study Group. Finasteride treatment of patterned hair loss in normoandrogenic postmenopausal women. Dermatology. 2004;209:202–207. [PubMed]
8. Carmina E, Lobo RA. Treatment of hyperandrogenic alopecia in women. Fertil Steril. 2003;79:91–95. [PubMed]
9. Shum KW, Cullen DR, Messenger AG. Hair loss in women with hyperandrogenism: four cases responding to finasteride. J Am Acad Dermatol. 2002;47:733–739. [PubMed]
10. Birch MP, Lalla SC, Messenger AG. Female pattern hair loss. Clin Exp Dermatol. 2002;27:383–388. [PubMed]
Articles from Annals of Dermatology are provided here courtesy of
Korean Dermatological Association and Korean Society for Investigative Dermatology